期刊文献+

GATA3在乳腺癌组织中的表达及其与ER表达的关系 被引量:5

Expression of GATA3 in breast cancer tissues and its relationship with ER expression
下载PDF
导出
摘要 目的:探讨乳腺癌组织中GATA3的表达及与ER表达的关系,以及GATA3在乳腺癌发生中的意义。方法:采用免疫组化方法检测了上海市黄浦区中心医院2004年至2005年间外科手术切除的100例乳腺癌组织和61例癌旁乳腺组织中GATA3的表达水平,分析其与ER表达和乳腺癌患者临床病理特征间的关系。结果:GATA3在癌旁乳腺组织中的阳性表达率(82.0%)明显高于乳腺癌组织(60.0%)(χ2=8.45,P<0.01),但在不同病理类型乳腺癌中表达无差异(χ2=0.74,P>0.05)GATA3的表达和患者年龄、肿瘤大小无关(P>0.05),与乳腺癌组织分级、淋巴结转移相关(P<0.05)。乳腺癌组织中GATA3的阳性表达与ER的阳性表达存在着显著的正相关(r=0.49,P<0.01)。结论:乳腺癌组织低表达GATA3,GATA3表达与ER表达正相、与乳腺癌的发生、发展、转移和预后相关。
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2011年第1期89-91,共3页 Chinese Journal of Cancer Biotherapy
基金 上海市黄浦区卫生事业发展基金资助项目( No. HWY-07156)~~
  • 相关文献

参考文献17

  • 1Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of hu- man breast tumors [ J]. Nature, 2000, 406(6797): 747-752.
  • 2Merika M, Orkin SH. DNA-binding specificity of GATA family transcription factors [J]. Mol Cell Biol, 1993, 13 (7) : 3999- 4010.
  • 3Pai SY, Truitt ML, Ho IC. GATA-3 deficiency abrogates the de- velopment and maintenance of T helper type 2 cells [ J ]. Proc Natl Acad Sci U S A, 2004, 101(7) : 1993-1998.
  • 4Kaufman CK, Zhou P, Pasolli HA, et al. GATA-3 : An unexpect- ed regulator of cell lineage determination in skin [ J]. Genes Dev, 2003, 17(17) : 2108-2122.
  • 5Kouros-Mehr H, Werb Z. Candidate regulators of mammary branching morphogenesis identified by genome-wide transcript analysis [J]. Dev Dyn, 2006, 235(5) : 3404-3412.
  • 6Ciocca V, Daskalakis C, Ciocca RM, et al. The significance of GATA3 expression in breast cancer: A 10-year follow-up study [J]. Hum Pathol, 2009, 40(4) : 489-495.
  • 7Joulin V, Bories D, Eleouet JF, et al. A T-cell specific TCR delta DNA binding protein is a member of the human GATA family [ J]. EMBO J, 1991, 10(7): 1809-1816.
  • 8Patient RK, McGhee JD. The GATA family (vertebrates and in- vertebrates) [J]. Curr Opin Genet Dev, 2002, 12(4): 416- 422.
  • 9Shackleton M, Vaillant F, Simpson KJ, et al. Generation of a functional mammary gland from a single stem cell [ J ]. Nature, 2006, 439(7072) : 84-88.
  • 10Stingl J, Eirew P, Ricketson I, et al. Purification and unique properties of mammary epithelial stem cells [ J]. Nature, 2006, 439 (7079) : 993-997.

同被引文献96

  • 1王启俊,祝伟星,邢秀梅.北京城区女性乳腺癌发病死亡和生存情况20年监测分析[J].中华肿瘤杂志,2006,28(3):208-210. 被引量:81
  • 2杜长征,李惠平,侯宽永,李强,赵红梅,王墨培.中国乳腺癌妇女表皮生长因子受体-2表达的Meta分析[J].北京大学学报(医学版),2006,38(2):184-188. 被引量:16
  • 3左文述,魏玲,宋现让,王兴武,王明玉,王永胜,于志勇,毕晔.浸润性乳腺癌组织中P-糖蛋白以及肺耐药蛋白和多药耐药相关蛋白表达的临床意义[J].中华医学杂志,2006,86(44):3142-3145. 被引量:9
  • 4孟洁,郎荣刚,范宇,付丽.年轻乳腺癌患者的病理学和生物学特征及其与预后的关系[J].中华肿瘤杂志,2007,29(4):284-288. 被引量:29
  • 5Hayashi N, Nakamura S, Tokuda Y, et al. Serum Her2 levels de- termined by two methods in patients with metastatic [ J ]. Int J Clin Oncol, 2012, 17(1) : 55-62.
  • 6Marry M, Cognetti F, Maraninchi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with do- cetaxel in patients with human epidermal growth factor receptor 2- positive metastatic breast cancer administered as first-line treat- ment: The M77001 study group [J]. J Clin Oncol, 2005, 23 (19) : 4265-4274.
  • 7Zvia A, Oleg UK, Genadiy V, et al. Dickkopfl regulates fate de- cision and drives breast cancer stem cells to differentiation: An ex- perimentally supported mathematical model [ J ]. PLoS One, 2011, 6(9) : e24225.
  • 8Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adju- vant chemotherapy for operable Her2-positive breast cancer [ J ]. N Engl J Med, 2005, 353(16) : 1673-1684.
  • 9Perez EA, Suman VJ, Davidson NE, et al. Results of chemother- apy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 Her2-positive adjuvant breast cancer trial [J]. Cancer Res, 2010, 70( 13): 5640-5641.
  • 10Ohno S, Tanaka K, Koga C, et al. Can patients with metastatic breast cancer be cured after introduction of newer and more effec- tive agents? [J]. Breast Cancer, 2012, 19(3) : 212-217.

引证文献5

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部